IBDEI3I7 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,751,0)
 ;;=INTRAVITREAL INJECTIONS^3^79
 ;;^UTILITY(U,$J,358.4,752,0)
 ;;=EDUCATION/COUNSELING^1^79
 ;;^UTILITY(U,$J,358.4,753,0)
 ;;=ANTERIOR SEGMENT^2^80
 ;;^UTILITY(U,$J,358.4,754,0)
 ;;=GLAUCOMA^4^80
 ;;^UTILITY(U,$J,358.4,755,0)
 ;;=INFECTIONS^5^80
 ;;^UTILITY(U,$J,358.4,756,0)
 ;;=LENS/CATARACT^6^80
 ;;^UTILITY(U,$J,358.4,757,0)
 ;;=LOW VISION/BLINDNESS^7^80
 ;;^UTILITY(U,$J,358.4,758,0)
 ;;=DIABETES^3^80
 ;;^UTILITY(U,$J,358.4,759,0)
 ;;=MOST COMMON & POST OP^1^80
 ;;^UTILITY(U,$J,358.4,760,0)
 ;;=NEUROLOGIC EYE DISEASE^8^80
 ;;^UTILITY(U,$J,358.4,761,0)
 ;;=ORBIT/EYELID/LACRIMAL^9^80
 ;;^UTILITY(U,$J,358.4,762,0)
 ;;=REFRACTION^10^80
 ;;^UTILITY(U,$J,358.4,763,0)
 ;;=RETINA/VITREOUS^11^80
 ;;^UTILITY(U,$J,358.4,764,0)
 ;;=STRABISMUS^12^80
 ;;^UTILITY(U,$J,358.4,765,0)
 ;;=SYSTEMIC/TRAUMA/OTHER^13^80
 ;;^UTILITY(U,$J,358.4,766,0)
 ;;=REFRACTION^1^81
 ;;^UTILITY(U,$J,358.4,767,0)
 ;;=GLASSES/CONTACT LENSES^2^81
 ;;^UTILITY(U,$J,358.4,768,0)
 ;;=SPECIAL OPHTHALMIC SERVICES^4^81
 ;;^UTILITY(U,$J,358.4,769,0)
 ;;=ANTERIOR SEGMENT^2^82
 ;;^UTILITY(U,$J,358.4,770,0)
 ;;=GLAUCOMA^4^82
 ;;^UTILITY(U,$J,358.4,771,0)
 ;;=INFECTIONS^5^82
 ;;^UTILITY(U,$J,358.4,772,0)
 ;;=LENS/CATARACT^6^82
 ;;^UTILITY(U,$J,358.4,773,0)
 ;;=LOW VISION/BLINDNESS^7^82
 ;;^UTILITY(U,$J,358.4,774,0)
 ;;=DIABETES^3^82
 ;;^UTILITY(U,$J,358.4,775,0)
 ;;=MOST COMMON & POST OP^1^82
 ;;^UTILITY(U,$J,358.4,776,0)
 ;;=NEUROLOGIC EYE DISEASE^8^82
 ;;^UTILITY(U,$J,358.4,777,0)
 ;;=ORBIT/EYELID/LACRIMAL^9^82
 ;;^UTILITY(U,$J,358.4,778,0)
 ;;=REFRACTION^10^82
 ;;^UTILITY(U,$J,358.4,779,0)
 ;;=RETINA/VITREOUS^11^82
 ;;^UTILITY(U,$J,358.4,780,0)
 ;;=STRABISMUS^12^82
 ;;^UTILITY(U,$J,358.4,781,0)
 ;;=SYSTEMIC/TRAUMA/OTHER^13^82
 ;;^UTILITY(U,$J,358.4,782,0)
 ;;=NEW PATIENT^2^83
 ;;^UTILITY(U,$J,358.4,783,0)
 ;;=ESTABLISHED PATIENT^1^83
 ;;^UTILITY(U,$J,358.4,784,0)
 ;;=CONSULTATIONS^3^83
 ;;^UTILITY(U,$J,358.4,785,0)
 ;;=BIOPSY/DEBRIDEMENT^1^84
 ;;^UTILITY(U,$J,358.4,786,0)
 ;;=I&D/ASPIRATION^4^84
 ;;^UTILITY(U,$J,358.4,787,0)
 ;;=DESTRUCT-BENIGN/PREMALIG LESIONS^2^84
 ;;^UTILITY(U,$J,358.4,788,0)
 ;;=SCOPES^7^84
 ;;^UTILITY(U,$J,358.4,789,0)
 ;;=EXCISION^3^84
 ;;^UTILITY(U,$J,358.4,790,0)
 ;;=MISCELLANEOUS^5^84
 ;;^UTILITY(U,$J,358.4,791,0)
 ;;=PEG TUBE^6^84
 ;;^UTILITY(U,$J,358.4,792,0)
 ;;=UNNA BOOT^8^84
 ;;^UTILITY(U,$J,358.4,793,0)
 ;;=WOUND VAC DRESSING^9^84
 ;;^UTILITY(U,$J,358.4,794,0)
 ;;=ABDOMINAL PAIN^1^85
 ;;^UTILITY(U,$J,358.4,795,0)
 ;;=AFTERCARE POST SURGERY^2^85
 ;;^UTILITY(U,$J,358.4,796,0)
 ;;=BENIGN LESIONS OF SKIN^3^85
 ;;^UTILITY(U,$J,358.4,797,0)
 ;;=BREAST-FEMALE^5^85
 ;;^UTILITY(U,$J,358.4,798,0)
 ;;=BREAST-MALE^6^85
 ;;^UTILITY(U,$J,358.4,799,0)
 ;;=CARDIOVASCULAR^7^85
 ;;^UTILITY(U,$J,358.4,800,0)
 ;;=CIRRHOSIS^8^85
 ;;^UTILITY(U,$J,358.4,801,0)
 ;;=COLITIS^9^85
 ;;^UTILITY(U,$J,358.4,802,0)
 ;;=CROHN'S^10^85
 ;;^UTILITY(U,$J,358.4,803,0)
 ;;=DIVERTICULITIS^11^85
 ;;^UTILITY(U,$J,358.4,804,0)
 ;;=DIVERTICULOSIS^12^85
 ;;^UTILITY(U,$J,358.4,805,0)
 ;;=ENT^13^85
 ;;^UTILITY(U,$J,358.4,806,0)
 ;;=GANGLION^14^85
 ;;^UTILITY(U,$J,358.4,807,0)
 ;;=GANGRENE^15^85
 ;;^UTILITY(U,$J,358.4,808,0)
 ;;=GENERAL SIGNS/SYMPTOMS^16^85
 ;;^UTILITY(U,$J,358.4,809,0)
 ;;=GI^17^85
 ;;^UTILITY(U,$J,358.4,810,0)
 ;;=GYN^18^85
 ;;^UTILITY(U,$J,358.4,811,0)
 ;;=HEMORRHOIDS^19^85
 ;;^UTILITY(U,$J,358.4,812,0)
 ;;=INTESTINAL ABSCESS^20^85
 ;;^UTILITY(U,$J,358.4,813,0)
 ;;=LACERATION^21^85
 ;;^UTILITY(U,$J,358.4,814,0)
 ;;=MALIGNANT SKIN LESION^23^85
 ;;^UTILITY(U,$J,358.4,815,0)
 ;;=MELANOMA^24^85
 ;;^UTILITY(U,$J,358.4,816,0)
 ;;=MERKEL CELL CARCINOMA^25^85
